Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research

Alcohol pharmacotherapies pose unknown teratogenic risks in pregnancy and are therefore recommended to be avoided. This limits treatment options for pregnant individuals with alcohol use disorders (AUD). The information on the safety of these medications during pregnancy is uncertain, prompting a scoping review. The objective of this review was to investigate available information on the safety of alcohol pharmacotherapies in pregnancy.

Research

Feto-placental vascular structure and in silico haemodynamics: Of mice, rats, and human

The complex arborization of the feto-placental vasculature is crucial for optimal fetal nutrition, waste exchange and ultimately, development. Ethical and experimental limitations constrain research into the human placenta, hence experimental animal models such as mice and rats, are crucial to understand placental function. It is unclear how well the mouse and rat feto-placental vascular structure emulates human. Moreover, the implications of differences in vascular structure, especially in arborization, for placental function remain unclear. 

Research

Predictive gene expression signature diagnoses neonatal sepsis before clinical presentation

Neonatal sepsis is a deadly disease with non-specific clinical signs, delaying diagnosis and treatment. There remains a need for early biomarkers to facilitate timely intervention. Our objective was to identify neonatal sepsis gene expression biomarkers that could predict sepsis at birth, prior to clinical presentation. 

News & Events

Top researchers recognised for respiratory research

Two leading researchers from The Kids received significant endorsements to advance their research at last night’s Thoracic Society of Australia and New Zealand and the Australian and New Zealand Society of Respiratory Science (TSANZSRS) Annual Scientific Meeting in Adelaide.

News & Events

Cure4CF Grant a boost for innovative Cystic Fibrosis research

A $350,000 Cure4 Cystic Fibrosis grant is set to propel the Wal-yan Respiratory Research Centre’s Phage WA program forward, supercharging its fight against antimicrobial resistant (AMR) lung infections in people with Cystic Fibrosis (CF) using  cutting-edge phage therapy.

News & Events

Respiratory researcher named joint winner of prestigious Premier’s Science Award

Congratulations to respiratory health researcher and clinician Dr Pam Laird, who was last night named joint winner of Early Career Scientist of the Year at the 2024 Premier’s Science Awards.

News & Events

Toxic, harmful chemicals found in popular Australian e-liquids

Perth researchers have found toxic and harmful chemicals in several dozen e-cigarette liquids readily available in Australia.

Research

The potential of antisense oligonucleotide therapies for inherited childhood lung diseases

Antisense oligonucleotides are an emerging therapeutic option to treat diseases with known genetic origin. In the age of personalised medicines, antisense oligonucleotides can sometimes be designed to target and bypass or overcome a patient's genetic mutation, in particular those lesions that compromise normal pre-mRNA processing. Antisense oligonucleotides can alter gene expression through a variety of mechanisms as determined by the chemistry and antisense oligomer design.

News & Events

Superviruses to fight superbugs: Perth's first phage manufacturing facility is officially open

Patients battling antibiotic-resistant superbugs will soon have access to life-saving WA-made therapies that could help treat lung, skin and ear infections as well as bacterial infections like Golden Staph. Western Australia's inaugural phage manufacturing facility – spearheaded by a team at the

News & Events

Research into chronic lung disease in Indigenous children and a novel RSV treatment boosted thanks to WACRF grants

Wal-yan Respiratory Research Centre researchers will use almost $1.2 million in WA Child Research Fund grants to determine why Indigenous children develop bronchiectasis at such high rates after contracting bronchiolitis, and to test a promising novel treatment for respiratory syncytial virus (RSV).